Apomorphine hydrochloride for the treatment of Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 15, Issue 7, 2015, Pages 723-732

  Unti, Elisa ^a   Ceravolo, Roberto ^a   Bonuccelli, Ubaldo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

apomorphine; disease; intermittent; motor fluctuations; Parkinson's; subcutaneous; therapy

Indexed keywords

APOMORPHINE; ANTIPARKINSON AGENT;

ANXIETY; BEHAVIOR DISORDER; BLADDER DYSFUNCTION; CONSTIPATION; DAYTIME SOMNOLENCE; DEMENTIA; DROWSINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; ELIMINATION HALF-LIFE; FATIGUE; HALLUCINATION; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; NAUSEA AND VOMITING; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; REVIEW; SMELLING; SOMNOLENCE; STOMACH EMPTYING; VOLUME OF DISTRIBUTION; CHEMISTRY; CLINICAL TRIAL (TOPIC); PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; APOMORPHINE; CLINICAL TRIALS AS TOPIC; HUMANS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84933517231     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1051468     Document Type: Review

References (72)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2006;373:2055-66
2. Merims D, Djaldetti R, Melamed E. Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations. Clin Neuropharmacol 2003;26:196-8
3. Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20:224-30
4. Doi H, Sakakibara R, Sato M, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease. J Neurol Sci 2012;319:86-8
5. Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in Parkinson's disease. Mov Disord 2014;29:23-32
6. Fernandez N, Garcia JJ, Diez MJ, et al. Effects of dietary factors on levodopa pharmacokinetics. Expert Opin Drug Metab Toxicol 2010;6:633-42
7. Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013;28:1241-9
8. Isaacson S, Chaudhuri KR. Morning akinesia and the potential role of gastroparesis -managing delayed onset of first daily dose of oral levodopa in patients with Parkinson's disease. Eur Neurolog Rev 2013;8:82-4
9. Kulizewsky J, Luquin MR, Arbelo JM, et al. Advanced Parkinson's disease: clinical characteristics and treatment. Part II. Neurología 2013;28:558-83
10. Swope DM. Rapid treatment of "wearing-off" in Parkinson's disease. Neurology 2004;62:S27-31
11. Muguet D, Broussolle E, Chazot G. Apomorphine in patients with Parkinson's disease. Biomed Pharmacother 1995;49:197-209
12. LeWitt PA. Subcutaneously administered apomorphine. Pharmacokinetics and metabolism. Neurology 2004;62:S8-S11
13. Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989;26:232-8
14. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 2006;45:109-36
15. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951;56:251-3
16. Cotzias GC, Papavasilious PS, Fehling C, et al. Similarities between neurological effects of L-dopa and apomorphine. N Engl J Med 1970;282:31-3
17. Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1979;51:954-6
18. Bonuccelli U, Piccini P, Del Dotto P, et al. "Apomorphine test for dopaminergic responsiveness: a dose assessment study". Mov Disord 1993;8:158-64
19. Roth J, Ruzicka E, Mecir P. The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience. Cas Lek Cesk 1994;133:665-7
20. Clarke CE, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:590-4
21. Luquin MR, Scipioni O, Vaamonde J, et al. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-24
22. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain 1984;107:487-506
23. Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;1:403-6
24. Kempster PA, Frankel JP, Stern GM, Lees AJ. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:1004-7
25. Van Laar T. A double-blind study of the efficacy of apomorphine and its assessment in "off"-periods in Parkinson's disease. Clin Neurol Neurosurg 1993;95:231-5
26. Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson's disease: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;58:681-7
27. Merello M, Pikielny R, Cammarota A, Leiguarda R. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double blind single-dose study. Clin Neuropharmacology 1997;20:165-7
28. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101
29. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years. Mov Disord 1993;8:165-70
30. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late state Parkinson's disease: A longterm follow up. J Neurol Neurosurg Psychiatry 1998;65:709-16
31. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58:1385-92
32. Pfeiffer RF, Gutmann L, Hull KL Jr, et al. The APO302 Study Investigators. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat Disord 2007;13:93-100
33. Stacy M, Silver D. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. Parkinsonism Relat Disord 2008;14:85-92
34. Pahwa R, Koller WC, Trosch RM, Sherry JH. APO303 Study Investigators. Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 2007;258:137-43
35. Trosch RM, Silver D, Bottini PB. Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study. CNS Drugs 2008;22:519-27
36. LeWitt PA, Ondo WG, Van Lunen B, Bottini PB. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off"episodes in advanced Parkinson disease. Clin Neuropharmacol 2009;32:89-93
37. Isaacson S. Apomorphine penject - emerging evidence and treatment strategies for delayed On and Off periods in Parkinson's disease. Eur Med J Neurol 2014;1:27-35
38. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004;21:687-709 A well written review on the use of apomorphine in PD patients.
39. Lertxundi U, Domingo-Echaburu S, Soraluce A, et al. Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard? Curr Drug Saf 2013;8:63-8
40. Chaudhuri KR, Healy D, Schapira AHV. The non-motor symptoms of Parkinson's disease. Diagnosis and management. Lancet Neurol 2006;5:235-45
41. Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989;46:1061-4
42. Edwards LL, Quigley EM, Harned RK, et al. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 1993;33:490-3
43. Rossi M, Merello M, Perez-Lloret S. Management of constipation in Parkinson's disease. Expert Opin Pharmacother 2014;16:4
44. Tison F, Wiart L, Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. Mov Disord 1996;11:729-32
45. Garcia Ruiz PJ. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease. Mov Disord 2006;21:727-8
46. Tribl GG, Sycha T, Kotzailias N, et al. Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatr 2005;76:181-5
47. Haba-Rubio J, Staner L, Cornette F, et al. Acute low single dose of apomorphine reduces periodic limb movements but has no significant effect on sleep arousals: a preliminary report. Neurophysiol Clin 2003;33:180-4
48. Priano L, Albani G, Brioschi A, et al. Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment. Neurol Sci 2003;24:207-8
49. Christmas TJ, Kempster PA, Chapple CR, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988;2:1451-3
50. Magennis B, Cashell A, O'Brien D, Lynch T. An audit of apomorphine in the management of complex idiopathic Parkinson's disease in Ireland. Mov Disord 2012;27:S44
51. Todorova A, Martin A, Okai D, et al. Assessment of impulse control disorders in Parkinson's patients with infusion therapies: a single centre experience. Mov Disord 2013;28:S133
52. Garcia-Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous- apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicentre study. Mov Disord 2008;23:1130-6
53. Corsini GU, Pitzalis GF, Bemardi F, et al. The use of dopamine agonists in the treatment of schizophrenia. Neuropharmacology 1981;20:1309-13
54. Ellis C, Lemmens G, Parkes JD, et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord 1997;3:103-7
55. Ahmad N, Keith-Ferris J, Gooden E, Abell T. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 2006;6:571-6
56. Cameron HA, Reyntjens AJ, Lake-Bakaar G. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed) 1985;290:160
57. Giaccone G, Berletto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet 1984;2:1336-7
58. Osborne RJ, Sleven ML, Hunter RW, Hamer J. Cardiotoxicity of intravenous domperidone. Lancet 1985;2:385
59. Johannes CB, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf 2010;19:881-8
60. Domperidone: small risk of serious ventricular arrhythmia and sudden cardiac death. Drug Saf Update 2012;5:A2
61. Chen JJ, Obering C. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associate with advanced Parkinson's disease. Clin Ther 2005;27:1710-24
62. Hauser RA, Isaacson S, Clinch T; The Tigan/Apokyn Study Investigators. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord 2014;20:1171-6
63. Deffond D, Durif F, Tournillac M. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes. J Neurol Neurosurg Psychiatry 1993;56:101-3
64. Dewey RB, Maraganore DM, Ahlskog JE, Matsumoto JY. A. double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for Off-States in Parkinson's disease. Mov Disord 1998;13:782-7
65. Grosset KA, Malek N, Morgan F, et al. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing 'off' periods in patients with established Parkinson's disease. Eur J Neurol 2013;20:1445-50
66. Todorova A, Chaudhuri KR. Subcutaneous apomorphine and non-motor symptoms in Parkinson's Disease. Parkinsonism Relat Disord 2013;19:1073-8
67. Poewe W, Kleedorfer B, Gerstenbrand F, Oertel W. Subcutaneous apomorphine in Parkinson's disease. Lancet 1988;1:943
68. Pollak P, Champay AS, Hommel M, et al. Subcutaneous apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989;52:544
69. Poewe W, Kleedorfer B, Wagner M, et al. Side-effects of subcutaneous apomorphine in Parkinson's disease. Lancet 1989;1:1084-5
70. Hughes AJ, Lees AJ, Stern GM. The motor response to sequential apomorphine in parkinsonian fluctuations. J Neurol Neurosurg Psychiatry 1991;54:358-60
71. Hughes AJ, Bishop S, Stern GM, Lees AJ. The motor response to repeated apomorphine administration in Parkinson's disease. Clin Neuropharmacol 1991;14:209-13
72. Gervason CL, Pollak PR, Limousin P, Perret JE. Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease. Clin Neuropharmacol 1993;16:113-19